Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4098S | ISIN: US6963894026 | Ticker-Symbol: 7NS0
Lang & Schwarz
21.11.24
07:00 Uhr
3,200 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALISADE BIO INC Chart 1 Jahr
5-Tage-Chart
PALISADE BIO INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,1203,28007:00

Aktuelle News zur PALISADE BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:19Palisade Bio, Inc.: Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)1
14.11.Palisade Bio, Inc.: Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit1
PALISADE BIO Aktie jetzt für 0€ handeln
12.11.Palisade Bio, Inc.: Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-210858Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio...
► Artikel lesen
07.11.Palisade Bio startet Phase-1-Studie für neues Colitis-ulcerosa-Medikament-
07.11.Palisade Bio initiates phase 1 study of new UC drug1
31.10.Palisade Bio advances novel IBD treatment PALI-21082
31.10.Palisade Bio, Inc.: Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis411Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially...
► Artikel lesen
30.10.PALI stock touches 52-week low at $3.09 amid market fluctuations1
30.10.PALI-Aktie erreicht 52-Wochen-Tief bei 3,09 US-Dollar1
10.10.Palisade Bio, Inc.: Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)71- Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) - The study is a Phase 1 Single Ascending Dose (SAD) /Multiple...
► Artikel lesen
27.09.Palisade Bio schließt neuen Vertrag mit CEO Finley; Konditionen offengelegt2
27.09.Palisade Bio inks new deal with CEO Finley; terms disclosed4
27.09.PALISADE BIO, INC. - 8-K, Current Report1
25.09.PALI-Aktie erreicht 52-Wochen-Tief bei 3,3 US-Dollar4
25.09.PALI stock touches 52-week low at $3.3 amid market fluctuations1
25.09.Palisade Bio, Inc.: Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis81- Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose - Completion of pre- Clinical Trial Application (CTA) meeting...
► Artikel lesen
16.09.Palisade Bio bolsters branding with bold new logo, website makeover-
13.08.Palisade Bio Edges up on Q2 Results7
13.08.Palisade Bio GAAP EPS of -$3.322
13.08.Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update155- Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end - Company continues to...
► Artikel lesen
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1